Kairos Pharma, Ltd. announced it has been named a winner of the 2026 Biotech Breakthrough Awards in the category of Cancer Immunology Solution of the Year. The recognition is for its lead candidate ENV-105 (carotuximab), an investigational antibody targeting cancer drug resistance in metastatic prostate cancer and non-small cell lung cancer. Kairos Pharma operates as a clinical-stage biopharmaceutical company focused on oncology therapeutics.
